Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019

NEXT STORY
Teladoc Health to Develop First Pediatric-Specific Consumer Telehealth Platform with Cincinnati Children’s
PREV STORY
Aleafia Health Increases Strategic Investment in Australian LP CannaPacific
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy

author_avatar
NASDAQ Market News

VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference

author_avatar
NASDAQ Market News

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

author_avatar
NASDAQ Market News